Neuren FDA meeting confirms Phase 3 plan for Rett syndrome
(World News Science)

Neuren (NEU) - ASX Announcement 13 October 2017 Neuren confirms Phase 3 plan for Rett syndrome at FDA Meeting Melbourne, Australia, 13 October 2017: Neuren Pharmaceuticals (ASX: NEU) today announced that at its End of Phase 2 Meeting, the US Food and Drug Administration agreed with Neuren`s proposal for the key elements of its clinical development program to support a New Drug Application for trofinetide to treat children and adults with Rett syndrome. Neuren will conduct a single pivotal Phase...